SOX11+ breast tumours display reactivated embryonic developmental signalling and organogenetic features and are at elevated risk of developing metastases, so may benefit from more aggressive therapies.
Cancer systems immunology is a highly interdisciplinary field that is advancing our ability to understand and predict the complex behavior that orchestrates the interplay between tumors and the immune system.
An unrecognized regulation on MAGEA protein stability promotes pancreatic cancer progression via manipulating autophagy and may impact the clinical utility of MAGEA-targeted immunotherapy.
A new knock-in mouse endogenously labels cytotoxic granules and can be used with all modern super-resolution imaging techniques to study T cell function in vitro and in vivo.
A biomimetic and patient-specific Glioblastoma-on-a-Chip microphysiological system provides an avenue for personalized screening of PD-1 immunotherapy and novel combinational therapies that maximize therapeutic outcomes in Glioblastoma patients.
An ancient integration of an endogenous retroelement in the gene encoding PD-L1 is exapted to generate a soluble form that antagonises the suppressive function of the membrane-bound form.
Proteomics and functional genomics coupled to an antibody discovery pipeline revealed the influence of oncogenic RAS signaling on the cell-surface proteome and resulted in the discovery of potential therapeutic targets for RAS-driven cancers.
